In February 1-2, 2026, Suzhou Senbomed Medical Technology Co.,Ltd made a remarkable appearance at the ECU – CRACM Joint International Pharmacy Conference (JIPC 2026) in Egypt, marking a pivotal step in our global layout and deepening cooperation with the Egyptian pharmaceutical industry. This event was a resounding success, where we not only showcased our cutting-edge medical device manufacturing strength but also fully demonstrated our capability to provide one-stop full industry chain solutions backed by China's robust pharmaceutical industrial resources and industrial chain advantages.

At JIPC 2026, we brought our core product portfolio to Egyptian partners and industry peers, including high-performance injection pens, innovative inhalation devices (SMI, Smart DPI, DPI, pMDI), precision nasal delivery devices and customizable tailor-made medical devices. Every product embodies our unwavering pursuit of quality – from ISO 13485 and GMP compliance, to ±5% dosing accuracy of injection pens, over 50% lung deposition rate of SMI, and a complete patent layout for core technologies, all of which have won high recognition and extensive attention from the Egyptian market.

Beyond world-class products, what we highlighted more at the conference is our core positioning as a China Pharma Industry Platform. Leveraging China's most complete and self-sufficient pharmaceutical industry chain – from abundant API raw materials, professional formulation development, to comprehensive medical device manufacturing and end-to-end regulatory clinical support – we build a solid bridge for resource integration between China and Egypt. Our platform empowers Egyptian partners with tangible value: direct access to China's top pharmaceutical enterprises, over 30% cost reduction through industrial chain synergy, and mature supply chain risk control to avoid market volatility.

Egypt's pharmaceutical industry is booming with huge development potential, and China's pharmaceutical industry boasts advanced technology, massive production capacity and rich industrial dividends. At JIPC 2026, we in-depth communicated with Egyptian industry insiders on the pain points and demands of the local market, including localized production, industrial technological upgrading and effective cost control. We put forward a clear three-step cooperation path: starting with cost-effective medical device product collaboration to build initial market trust, deepening technical exchange through standard sharing and personnel training, and finally achieving in-depth cooperation such as technology transfer, local production and joint R&D. Our one-stop supporting services, covering regulatory registration, compliance consulting and resource connection, will also provide a full range of guarantees for the smooth progress of bilateral cooperation.

This Egyptian trip is more than an exhibition and exchange; it is the sowing of hope for long-term cooperation between SENBOMED and the Egyptian pharmaceutical industry. We are committed to leveraging China's pharmaceutical industrial strength and our own platform advantages to empower the upgrading of Egypt's local pharmaceutical industry, co-build a thriving China-Egypt healthcare cooperation ecosystem, and ultimately ensure that Egyptian patients have access to better and more affordable medical treatments.